Nasal insulin gel as an alternate to parenteral insulin: Formulation, preclinical, and clinical studies

AAPS PharmSciTech

Volumn 6, Issue 2, 2005, Pages

  D'Souza, Reshma ^a   Mutalik, Srinivas ^a   Venkatesh, ^a   Vidyasagar, Sudha ^b   Udupa, Nayanabhirama ^a  

^a MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

^b KASTURBA MEDICAL COLLEGE   (India)

Author keywords

Carbopol; Clinical; Diabetes mellitus; Gel; Insulin; Nasal; Preclinical

Indexed keywords

CARBOMER; GLUCOSE; HYDROXYPROPYLMETHYLCELLULOSE; INSULIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; MALE; NONHUMAN; NORMAL HUMAN; NOSE CAVITY; NOSE MUCOSA; PH; RAT; STREPTOZOCIN DIABETES; TIME; VISCOSITY; VOLUNTEER; ANIMAL; BLOOD; CATTLE; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; GEL; INFUSION; INTRANASAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; PHASE 1 CLINICAL TRIAL; SPRAGUE DAWLEY RAT;

ADMINISTRATION, INTRANASAL; ANIMALS; BLOOD GLUCOSE; CATTLE; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GELS; INFUSIONS, PARENTERAL; INSULIN; MALE; NASAL MUCOSA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 27744573524     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt060227     Document Type: Article

References (13)

1. Pillai O, Panchagnula R. Insulin therapies - past, present and future. Drug Discov Today. 2001;6:1056-1061.
2. Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacotherapy of the endocrine pancreas. In: Hardman JG, Limbird LE, eds. The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw-Hill; 1996:1487-1517.
3. Arunachalam S, Gunasekaran S. Diabetic research in India and China today: from literature-based mapping to health-care policy. Curr Sci. 2002;9-10:1086-1097.
4. Ugwoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol. 2001;53:3-22.
5. Jiang G, Qiu W, DeLuca PP. Preparation and in vitro/in vivo evaluation of insulin-loaded poly(acryloyl-hydroxyethyl starch)-PLGA composite microspheres. Pharm Res. 2003;20:452-459.
6. Khan Ghilzai NM. New developments in insulin delivery. Drug Dev Ind Pharm. 2003;29:253-265.
7. Shahiwala A, Misra A. Pulmonary absorption of liposomal levonorgestrel. AAPS PharmSciTech. 2004;5:E13.
8. Sanna V, Kirschvink N, Gustin P, et al. Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary adiministration. AAPS PharmSciTech. 2004;5:E27.
9. Grover JK, Rathi SS, Vats V. Amelioration of experimental diabetic neuropathy and gastropathy in rats following oral administration of plant (Eugenia jambolana, Mucurna pruriens and Tinospora cordifolia) extracts. Indian J Exp Biol. 2002;40:273-276.
10. Illum L, Davis SS. Microspheres for nasal administration. In: Duchene D, ed. Buccal and Nasal Administration as an Alternative for Parenteral Administration. Paris, France: Edition de Sante; 1992:125-137.
11. Moses AC, Gordon GS, Carey MC, Flier JS. Insulin administered as an insulin-bile salt aerosol: effectiveness and reproducibility in normal and diabetic subjects. Diabetes. 1983;32:1040-1047.
12. Gizurarson S. The relevance of nasal physiology to the design of drug absorption studies. Adv Drug Deliv Rev. 1993;11:329-347.
13. Singh S. Drug stability testing and shelf life determination according to international guidelines. Pharm Tech. 1999;7:69-79.